Company news

Galectin Therapeutics Inc. news in 2021

Galectin Therapeutics Inc.'s news releases, calls and decks from 2021, newest first.

View company

Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein

December 20, 2021

Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting

December 12, 2021

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2021, and Provides Business Update

November 14, 2021

UPDATE – Galectin Therapeutics to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD

November 4, 2021

Galectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD

October 26, 2021

UPDATE: Galectin Therapeutics to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021

October 4, 2021

Galectin Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

October 4, 2021

Galectin Therapeutics Announces $20 Million Convertible Debt Financing from Its Chairman, Richard E. Uihlein

September 20, 2021

Galectin Therapeutics, Inc. to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

September 8, 2021

Galectin Therapeutics Strengthens Leadership Team with Strategic Hires to Advance Programs in Cancer Immunotherapy and NASH Cirrhosis

August 29, 2021

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2021, and Provides Business Update

August 15, 2021

Galectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in Combination with KEYTRUDA® in Advanced Metastatic Melanoma and Head and Neck Cancer

July 8, 2021

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2021, and Provides Business Update

May 16, 2021

Galectin Therapeutics to Present at 4th Global NASH Congress

April 26, 2021

World-Renowned Neurosurgeon Dr. Ben Carson, Sr. Joins Galectin Therapeutics as Special Consultant to Accelerate and Enhance Development of Company’s Galectin-3 Inhibitor, Belapectin

April 18, 2021

Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics’ Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy

April 12, 2021

Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians about its Innovative NASH Cirrhosis Study

April 5, 2021

Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update

March 30, 2021

OncoImmunology Publishes Pre-clinical Research Showing Galectin Therapeutics’ Belapectin Galectin-3 Inhibitor Reduces Tumor Progression in Combination with Anti-OX40 Therapy

March 7, 2021

Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference

March 3, 2021

Decks in 2021